Acurx Pharmaceuticals (ACXP) investor relations material

Company overview and business model

• Late-stage biopharmaceutical company developing small molecule antibiotics targeting difficult-to-treat Gram-positive bacterial infections, including C. difficile, MRSA, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae.

• Focuses on antibiotic candidates that inhibit DNA polymerase IIIC, leading to bacterial cell death; targets pathogens identified as priorities by WHO, CDC, and FDA.

• Organized in Delaware in 2017, commenced operations in 2018, and converted to a corporation in 2021.

Financial performance and metrics

• As of September 30, 2025, net tangible book value was $3.6 million ($2.02 per share); after the offering, as adjusted net tangible book value would be $5.3 million ($2.08 per share).

• Immediate dilution to new investors is estimated at $0.285 per share at an assumed offering price of $2.365.

• Company has never declared or paid cash dividends and intends to retain future earnings.

Use of proceeds and capital allocation

• May receive up to $7.6 million in gross proceeds from sales of common stock to Lincoln Park under the Purchase Agreement, in addition to $4.4 million previously received.

• Proceeds will be used for working capital and general corporate purposes, including R&D and administrative expenses; management has broad discretion over use.